Evidence map›Paper›PMID 32340203›Full record

ArticleMolecules (Basel, Switzerland)2020

Three-Component Access to Functionalized Spiropyrrolidine Heterocyclic Scaffolds and Their Cholinesterase Inhibitory Activity.

Sarra Boudriga, Saoussen Haddad, Vikneswaran Murugaiyah, Moheddine Askri, Michael Knorr, Carsten Strohmann, Christopher Golz

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sarra BoudrigaDepartment of Chemistry, Laboratory of Heterocyclic Chemistry Natural Product and Reactivity/CHPNR, Faculty of Science of Monastir, Monastir 5000, Tunisia.
Saoussen HaddadDepartment of Chemistry, Laboratory of Heterocyclic Chemistry Natural Product and Reactivity/CHPNR, Faculty of Science of Monastir, Monastir 5000, Tunisia.
Vikneswaran MurugaiyahDiscipline of Pharmacology, School of Pharmaceutical Sciences, Universiti Sains Malaysia, USM 11800, Penang, Malaysia.
Moheddine AskriDepartment of Chemistry, Laboratory of Heterocyclic Chemistry Natural Product and Reactivity/CHPNR, Faculty of Science of Monastir, Monastir 5000, Tunisia.
Michael KnorrInstitut UTINAM-UMR CNRS 6213, Université Bourgogne Franche-Comté, 16 Route de Gray, 25030 Besançon, France.ORCID 0000-0002-5647-8084
Carsten StrohmannTechnische Universität Dortmund, Anorganische Chemie Otto-Hahn-Straße 6, 44221 Dortmund, Germany.ORCID 0000-0002-4787-2135
Christopher GolzTechnische Universität Dortmund, Anorganische Chemie Otto-Hahn-Straße 6, 44221 Dortmund, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A novel

Indexed as

Cholinesterase InhibitorsModels, MolecularMolecular ConformationMolecular StructureProtein BindingPyrrolidinesSpectrum AnalysisSpiro CompoundsStructure-Activity RelationshipCholinesterase InhibitorspyrrolidinePyrrolidinesSpiro Compounds[3+2]-cycloaddition reactionazomethine ylidesdispiropyrrolidine derivativessuccinimide

Identifiers

PMID32340203
PMCPMC7221748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.